Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNN3 | Q9UGI6 | 4/20 | 0.36 |
| ▸ | CNR2 | P34972 | 3/20 | 0.34 |
| ▸ | CNR1 | P21554 | 1/20 | 0.34 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.34 |
| ▸ | CCR2 | P41597 | 3/20 | 0.32 |
| ▸ | TTR | P02766 | 1/20 | 0.32 |
| ▸ | RNASEH1 | O60930 | 1/20 | 0.32 |
| ▸ | KCNN1 | Q92952 | 1/20 | 0.32 |
| ▸ | KCNN2 | Q9H2S1 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | MBOAT4 | Q96T53 | 2/20 | 0.31 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15274725 | 0.82 | HTT (0.37) | KCNN3PDE10ACCR2RNASEH1KCNN1 | |
| SCHEMBL901640 | 0.81 | PRKAB2 (0.36) | KCNN3CNR2CNR1PDE10ACCR2 | |
| SCHEMBL902482 | 0.81 | PDE10A (0.33) | KCNN3PDE10ACCR2RNASEH1KCNN1 | |
| SCHEMBL902335 | 0.80 | PRKAB2 (0.38) | KCNN3PDE10ACCR2RNASEH1KCNN1 | |
| SCHEMBL901553 | 0.79 | CCR2 (0.46) | KCNN3PDE10ACCR2RNASEH1KCNN1 | |
| SCHEMBL902587 | 0.79 | RNASEH1 (0.46) | KCNN3PDE10ACCR2RNASEH1KCNN1 | |
| SCHEMBL901430 | 0.78 | CCR2 (0.47) | KCNN3PDE10ACCR2RNASEH1KCNN1 | |
| SCHEMBL901506 | 0.78 | RNASEH1 (0.38) | PDE10ACCR2RNASEH1TSHR | |
| SCHEMBL902398 | 0.77 | PRKAB2 (0.34) | KCNN3CNR2PDE10ACCR2TSHR | |
| SCHEMBL901794 | 0.76 | RNASEH1 (0.37) | KCNN3CCR2RNASEH1KCNN1KCNN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130252951-A1 | 7-HYDROXY-PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS AND THEIR USE AS CCR2 RECEPTOR ANTAGONISTS | PROXIMAGEN LIMITED (GB) | 2013-09-26 | — | — | US | disclosed |
| US-20130252951-A1 | 7-HYDROXY-PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS AND THEIR USE AS CCR2 RECEPTOR ANTAGONISTS | PROXIMAGEN LIMITED (GB) | 2013-09-26 | — | — | US | disclosed |
| EP-2621928-A1 | 7-HYDROXY-PYRAZOLO[1,5-A]PYRIMIDINE COMPOUNDS AND THEIR USE AS CCR2 RECEPTOR ANTAGONISTS | Proximagen Limited (GB) | 2013-08-07 | — | — | EP | disclosed |
| WO-2012041817-A1 | 7-HYDROXY-PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS AND THEIR USE AS CCR2 RECEPTOR ANTAGONISTS | PROXIMAGEN LTD (GB) | 2012-04-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130252951-A1 | 7-HYDROXY-PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS AND THEIR USE AS CCR2 RECEPTOR ANTAGONISTS | CCR2, CCR5, CCR1 | KCNN3 4658/4885CNR2 97/4885CNR1 62/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.